ECOG Performance Status. 35 Date: 8 April 2016 v 2.1 INO-3112 UPCC # 39313 / Inovio HPV -005 Inovio Pharmaceuticals, Inc Clinical Protocol 5. Tumor Evaluation: Confirmation of diagnosis by histology and confirmation of p16 positivity. While biopsy tissue samples are undergoing confirmation of p16 positivity, the subject may proceed to other screening procedures and tests. However, the subject will be dosed only upon confirmation of p16 positivity or other pathological evidence of oncogenic HPV infection. Confirmation of diagnosis of surgically resec table HNSCCa. 6. 12-lead ECG . 7. Clinical laboratory testing including, but not limited to: CBC with differential and platelet count, PT, INR/ PTT, total serum bilirubin, alkaline phosphatase, AST (SGOT), ALT (SGPT), serum creatinine, serum electrolytes, serum calcium , serum albumin and CPK. Note: If clinical lab testing is performed within 28 days prior to study Day 0 as standard of care, the results can be used for screening and eligibility assessment. 8. Serology (HIV Ab, HCV Ab, HBsAg). 9. Serum beta HCG (for wom en of child bearing potential). 10. Adverse Event s 11. Whole blood and serum for baseline immunologic assays. 12. Paraffin -embedded tumor tissue or unstained slides for ISH and IHC. On the rare occasions where a subject is re- screened, the clinical labs and 12 -lead EC G must be repeated unless they occur within 4 weeks of the subject’s first dose. All other screening procedures do not need to be repeated. 6.1.2 Visit for Immunotherapy (Pre and Post surgery: Every 3 weeks ± 3 days) Subjects may receive up to 2 doses of immunotherapy prior to surgery and 1- 3 doses post -surgery as previously described. All sequential doses will be administered three weeks (± 3 days) apart. The following study evaluations will be performed prior to immunotherapy : 1. Confirmation of p16 positivity or other pathological evidence of oncogenic HPV infection. 2.